Pathways in the Diagnosis and Management of Diabetic Polyneuropathy

Current Diabetes Reports

Volumn 15, Issue 6, 2015, Pages 1-16

  Kaku, Michelle ^a   Vinik, Aaron ^b   Simpson, David M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b EASTERN VIRGINIA MEDICAL SCHOOL   (United States)

Author keywords

Diabetic; Diagnosis; Distal symmetric polyneuropathy; Multidisciplinary; Neuropathy; Treatment algorithm

Indexed keywords

ANTICONVULSIVE AGENT; CANNABINOID; CAPSAICIN; LIDOCAINE; OPIATE DERIVATIVE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; THIOCTIC ACID; TRICYCLIC ANTIDEPRESSANT AGENT;

ALGORITHM; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); COMORBIDITY; CONTROLLED CLINICAL TRIAL (TOPIC); DIABETIC NEUROPATHY; DIABETIC PATIENT; DIAGNOSTIC ERROR; DISTAL SYMMETRIC POLYNEUROPATHY; GENERAL PRACTITIONER; GLYCEMIC CONTROL; HEALTH CARE ACCESS; HUMAN; MEDICAL SPECIALIST; NURSE PRACTITIONER; PATHOPHYSIOLOGY; PATIENT EDUCATION; PATIENT REFERRAL; PATIENT SATISFACTION; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; TREATMENT INDICATION; TREATMENT OUTCOME; DIABETIC NEUROPATHIES; DISEASE MANAGEMENT; POLYNEUROPATHIES;

DIABETIC NEUROPATHIES; DISEASE MANAGEMENT; HUMANS; POLYNEUROPATHIES;

EID: 84928378048     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-015-0609-2     Document Type: Review

References (117)

1. Barrett AM, Lucero MA, Le T, et al. Epidemiology, public health burden, and treatment of diabetic peripheral neuropathic pain: a review. Pain Med. 2007;8 Suppl 2:S50–62.
2. Vileikyte L, Peyrot M, Gonzalez JS, et al. Predictors of depressive symptoms in persons with diabetic peripheral neuropathy: a longitudinal study. Diabetologia. 2009;52:1265–73.
3. Sadosky A, Schaefer C, Mann R, et al. Burden of illness associated with painful diabetic peripheral neuropathy among adults seeking treatment in the US: results from a retrospective chart review and cross-sectional survey. Diabetes Metab Syndr Obes. 2013;6:79–92.
4. Gordois A, Scuffham P, Shearer A, et al. The health care costs of diabetic peripheral neuropathy in the US. Diabetes Care. 2003;26:1790–5.
5. Moser JT, Langdon DR, Finkel RS, et al. The evaluation of peripheral neuropathy in youth with type 1 diabetes. Diabetes Res Clin Pract. 2013;100:e3–6.
6. Karabouta Z, Barnett S, Shield JP, et al. Peripheral neuropathy is an early complication of type 2 diabetes in adolescence. Pediatr Diabetes. 2008;9:110–4.
7. Thomas PK. Classification, differential diagnosis, and staging of diabetic peripheral neuropathy. Diabetes. 1997;46 Suppl 2:S54–7.
8. Boulton AJ, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28:956–62.
9. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33:2285–93.
10. Apfel SC, Asbury AK, Bril V, et al. Positive neuropathic sensory symptoms as endpoints in diabetic neuropathy trials. J Neurol Sci. 2001;189:3–5.
11. Papanas N, Vinik AI, Ziegler D. Neuropathy in prediabetes: does the clock start ticking early? Nat Rev Endocrinol. 2011;7:682–90.
12. Sharma KR, Cross J, Farronay O, et al. Demyelinating neuropathy in diabetes mellitus. Arch Neurol. 2002;59:758–65.
13. van Deursen RW, Sanchez MM, Ulbrecht JS, et al. The role of muscle spindles in ankle movement perception in human subjects with diabetic neuropathy. Exp Brain Res. 1998;120:1–8.
14. Morrison S, Colberg SR, Mariano M, et al. Balance training reduces falls risk in older individuals with type 2 diabetes. Diabetes Care. 2010;33:748–50.
15. Abbott CA, Carrington AL, Ashe H, et al. The North-West Diabetes Foot Care Study: incidence of, and risk factors for, new diabetic foot ulceration in a community-based patient cohort. Diabet Med. 2002;19:377–84.
16. Singh N, Armstrong DG, Lipsky BA. Preventing foot ulcers in patients with diabetes. JAMA. 2005;293:217–28.
17. Vinik AI, Casellini CM. Guidelines in the management of diabetic nerve pain: clinical utility of pregabalin. Diabetes Metab Syndr Obes. 2013;6:57–78.
18. The Diabetes Control and Complications Trial Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med. 1995;122:561–8.
19. Albers JW, Herman WH, Pop-Busui R, et al. Effect of prior intensive insulin treatment during the Diabetes Control and Complications Trial (DCCT) on peripheral neuropathy in type 1 diabetes during the Epidemiology of Diabetes Interventions and Complications (EDIC) Study. Diabetes Care. 2010;33:1090–6.
20. Martin CL, Albers JW, Pop-Busui R, et al. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37:31–8. This article reports the findings of the Epidemiology of Diabetes Interventions and Complications (EDIC) study, and discusses the clinical course of diabetic neuropathy and how it can be prevented.
21. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia. 1996;39:1377–84.
22. Dyck PJ, Clark VM, Overland CJ, et al. Impaired glycemia and diabetic polyneuropathy: the OC IG Survey. Diabetes Care. 2012;35:584–91.
23. Bongaerts BW, Rathmann W, Kowall B, et al. Postchallenge hyperglycemia is positively associated with diabetic polyneuropathy: the KORA F4 study. Diabetes Care. 2012;35:1891–3.
24. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care. 2006;29:1294–9.
25. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.
26. Gibbons CH, Freeman R. Treatment-induced diabetic neuropathy: a reversible painful autonomic neuropathy. Ann Neurol. 2010;67:534–41.
27. Vinik AI, Erbas T, Casellini CM. Diabetic cardiac autonomic neuropathy, inflammation and cardiovascular disease. J Diabetes Investig. 2013;4:4–18.
28. Calles-Escandón J, Lovato LC, Simons-Morton DG, et al. Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care. 2010;33:721–7.
29. Vinik AI, Maser RE, Ziegler D. Neuropathy: the crystal ball for cardiovascular disease? Diabetes Care. 2010;33:1688–90.
30. Llewelyn JG, Gilbey SG, Thomas PK, et al. Sural nerve morphometry in diabetic autonomic and painful sensory neuropathy. A clinicopathological study. Brain. 1991;114:867–92.
31. Archer AG, Watkins PJ, Thomas PK, et al. The natural history of acute painful neuropathy in diabetes mellitus. J Neurol Neurosurg Psychiatry. 1983;46:491–9.
32. Fernyhough P, Roy Chowdhury SK, Schmidt RE. Mitochondrial stress and the pathogenesis of diabetic neuropathy. Expert Rev Endocrinol Metab. 2010;5:39–49.
33. Stavniichuk R, Drel VR, Shevalye H, et al. Role of 12/15-lipoxygenase in nitrosative stress and peripheral prediabetic and diabetic neuropathies. Free Radic Biol Med. 2010;49:1036–45.
34. Stavniichuk R, Shevalye H, Lupachyk S, et al. Peroxynitrite and protein nitration in the pathogenesis of diabetic peripheral neuropathy. Diabetes Metab Res Rev. 2014;30:669–78.
35. Obrosova IG. Increased sorbitol pathway activity generates oxidative stress in tissue sites for diabetic complications. Antioxid Redox Signal. 2005;7:1543–52.
36. Kim B, Feldman EL. Insulin resistance in the nervous system. Trends Endocrinol Metab. 2012;23:133–41.
37. Callaghan BC, Cheng HT, Stables CL, et al. Diabetic neuropathy: clinical manifestations and current treatments. Lancet Neurol. 2012;11:521–34. This review outlines the clinical characteristics of diabetic neuropathy and provides an overview of analgesic treatment options, it also discusses potential future areas for research, with a particular focus on metabolic syndrome and the prevention of diabetic neuropathy.
38. Vinik AI, Nevoret ML, Casellini C, et al. Diabetic neuropathy. Endocrinol Metab Clin North Am. 2013;42:747–87. This comprehensive review discusses both the distinguishing characteristics of different types of neuropathy and the management of diabetic neuropathic pain. The review also gives background on the epidemiology and pathophysiology of diabetic neuropathy.
39. Baron R, Hans G, Dickenson AH. Peripheral input and its importance for central sensitization. Ann Neurol. 2013;74:630–6.
40. Vinik A. The approach to the management of the patient with neuropathic pain. J Clin Endocrinol Metab. 2010;95:4802–11.
41. Bourcier ME, Ullal J, Parson HK, et al. Diabetic peripheral neuropathy: how reliable is a homemade 1-g monofilament for screening? J Fam Pract. 2006;55:505–8.
42. O’Brien T, Karem J. Relative sensory sparing in the diabetic foot implied through vibration testing. Diabet Foot Ankle. 2013;4.
43. Tavee J, Zhou L. Small fiber neuropathy: a burning problem. Cleve Clin J Med. 2009;76:297–305.
44. McArthur JC, Stocks EA, Hauer P, et al. Epidermal nerve fiber density: normative reference range and diagnostic efficiency. Arch Neurol. 1998;55:1513–20.
45. Gibbons CH, Griffin JW, Polydefkis M, et al. The utility of skin biopsy for prediction of progression in suspected small fiber neuropathy. Neurology. 2006;66:256–8.
46. Devigili G, Tugnoli V, Penza P, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain. 2008;131:1912–25.
47. Young RJ, Ewing DJ, Clarke BF. Chronic and remitting painful diabetic polyneuropathy. Correlations with clinical features and subsequent changes in neurophysiology. Diabetes Care. 1988;11:34–40.
48. Leishear K, Boudreau RM, Studenski SA, et al. Relationship between vitamin B12 and sensory and motor peripheral nerve function in older adults. J Am Geriatr Soc. 2012;60:1057–63.
49. Fonseca VA, Lavery LA, Thethi TK, et al. Metanx in type 2 diabetes with peripheral neuropathy: a randomized trial. Am J Med. 2013;126:141–9.
50. Dyck PJ, Albers JW, Andersen H, et al. Diabetic polyneuropathies: update on research definition, diagnostic criteria and estimation of severity. Diabetes Metab Res Rev. 2011;27:620–8.
51. Feldman EL, Stevens MJ, Thomas PK, et al. A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care. 1994;17:1281–9.
52. Melzack R. The short-form McGill Pain Questionnaire. Pain. 1987;30:191–7.
53. Krause SJ, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain. 2003;19:306–14.
54. Zelman DC, Gore M, Dukes E, et al. Validation of a modified version of the Brief Pain Inventory for painful diabetic peripheral neuropathy. J Vasc Nurs. 2005;23:97–104.
55. Bouhassira D, Attal N, Fermanian J, et al. Development and validation of the Neuropathic Pain Symptom Inventory. Pain. 2004;108:248–57.
56. Boyd A, Casselini C, Vinik E, et al. Quality of life and objective measures of diabetic neuropathy in a prospective placebo-controlled trial of ruboxistaurin and topiramate. J Diabetes Sci Technol. 2011;5:714–22.
57. Vileikyte L, Peyrot M, Bundy C, et al. The development and validation of a neuropathy- and foot ulcer-specific quality of life instrument. Diabetes Care. 2003;26:2549–55.
58. Votrubec M, Thong I. Neuropathic pain—a management update. Aust Fam Physician. 2013;42:92–7.
59. Robertson RP, Sutherland DE. Pancreas transplantation as therapy for diabetes mellitus. Annu Rev Med. 1992;43:395–415.
60. Boyd AL, Barlow PM, Pittenger GL, et al. Topiramate improves neurovascular function, epidermal nerve fiber morphology, and metabolism in patients with type 2 diabetes mellitus. Diabetes Metab Syndr Obes. 2010;3:431–7.
61. Tesfaye S, Vileikyte L, Rayman G, et al. Painful diabetic peripheral neuropathy: consensus recommendations on diagnosis, assessment and management. Diabetes Metab Res Rev. 2011;27:629–38. This comprehensive review of painful diabetic neuropathy includes discussion on both the diagnosis and treatment of diabetic neuropathy, as well as highlighting some of the limitations of the existing evidence base supporting these treatments.
62. Dworkin RH, O’Connor AB, Kent J, et al. Interventional management of neuropathic pain: NeuPSIG recommendations. Pain. 2013;154:2249–61.
63. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113–23.
64. National Institute for Health and Clinical Excellence. Neuropathic pain – pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist settings. 2013. http://www.nice.org.uk/guidance/cg173. Accessed 24 June 2014.
65. Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76:1758–65.
66. Hartemann A, Attal N, Bouhassira D, et al. Painful diabetic neuropathy: diagnosis and management. Diabetes Metab. 2011;37:377–88.
67. Handelsman Y, Mechanick JI, Blonde L, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract. 2011;17 Suppl 2:1–53.
68. Spallone V. Management of painful diabetic neuropathy: guideline guidance or jungle? Curr Diab Rep. 2012;12:403–13.
69. Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3–14.
70. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150:573–81.
71. Raskin J, Smith TR, Wong K, et al. Duloxetine versus routine care in the long-term management of diabetic peripheral neuropathic pain. J Palliat Med. 2006;9:29–40.
72. Rull JA, Quibrera R, González-Millán H, et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia. 1969;5:215–8.
73. Wilton TD. Tegretol in the treatment of diabetic neuropathy. S Afr Med J. 1974;48:869–72.
74. Jose VM, Bhansali A, Hota D, et al. Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy. Diabet Med. 2007;24:377–83.
75. Eisenberg E, Lurie Y, Braker C, et al. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology. 2001;57:505–9.
76. Vinik AI, Tuchman M, Safirstein B, et al. Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies. Pain. 2007;128:169–79.
77. Silver M, Blum D, Grainger J, et al. Double-blind, placebo-controlled trial of lamotrigine in combination with other medications for neuropathic pain. J Pain Symptom Manage. 2007;34:446–54.
78. Vinik A, Emir B, Cheung R, et al. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Ther. 2013;35:612–23.
79. Freeman R, Raskin P, Hewitt DJ, et al. Randomized study of tramadol/acetaminophen versus placebo in painful diabetic peripheral neuropathy. Curr Med Res Opin. 2007;23:147–61.
80. Harati Y, Gooch C, Swenson M, et al. Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology. 1998;50:1842–6.
81. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011;27:151–62.
82. Vinik AI, Shapiro DY, Rauschkolb C, et al. A randomized-withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic, painful diabetic peripheral neuropathy. Diabetes Care. 2014;37:2302–9.
83. Janssen Pharmaceuticals I. Highlights of prescribing information: Nucynta® ER (tapentadol) extended-release oral tablets C-II. 2014. https://www.nucynta.com/shared/product/nucynta/nucyntaer-pi.pdf. Accessed 24 June 2014.
84. Simpson DM, Messina J, Xie F, et al. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29:588–601.
85. Ko SH, Kwon HS, Yu JM, et al. Comparison of the efficacy and safety of tramadol/acetaminophen combination therapy and gabapentin in the treatment of painful diabetic neuropathy. Diabet Med. 2010;27:1033–40.
86. Hanna M, O’Brien C, Wilson MC. Prolonged-release oxycodone enhances the effects of existing gabapentin therapy in painful diabetic neuropathy patients. Eur J Pain. 2008;12:804–13.
87. Gilron I, Bailey JM, Tu D, et al. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352:1324–34.
88. Zin CS, Nissen LM, O’Callaghan JP, et al. A randomized, controlled trial of oxycodone versus placebo in patients with postherpetic neuralgia and painful diabetic neuropathy treated with pregabalin. J Pain. 2010;11:462–71.
89. Ellis RJ, Toperoff W, Vaida F, et al. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34:672–80.
90. Abrams DI, Jay CA, Shade SB, et al. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68:515–21.
91. Selvarajah D, Gandhi R, Emery CJ, et al. Randomized placebo-controlled double-blind clinical trial of cannabis-based medicinal product (Sativex) in painful diabetic neuropathy: depression is a major confounding factor. Diabetes Care. 2010;33:128–30.
92. Mijnhout GS, Kollen BJ, Alkhalaf A, et al. Alpha lipoic acid for symptomatic peripheral neuropathy in patients with diabetes: a meta-analysis of randomized controlled trials. Int J Endocrinol. 2012;2012:456279.
93. Ziegler D, Low PA, Litchy WJ, et al. Efficacy and safety of antioxidant treatment with alpha-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care. 2011;34:2054–60.
94. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care. 2006;29:2365–70.
95. Han T, Bai J, Liu W, et al. A systematic review and meta-analysis of α-lipoic acid in the treatment of diabetic peripheral neuropathy. Eur J Endocrinol. 2012;167:465–71.
96. Tandan R, Lewis GA, Krusinski PB, et al. Topical capsaicin in painful diabetic neuropathy. Controlled study with long-term follow-up. Diabetes Care. 1992;15:8–14.
97. The Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med. 1991;151:2225–9.
98. Backonja M, Wallace MS, Blonsky ER, et al. NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia: a randomised, double-blind study. Lancet Neurol. 2008;7:1106–12.
99. Irving GA, Backonja MM, Dunteman E, et al. A multicenter, randomized, double-blind, controlled study of NGX-4010, a high-concentration capsaicin patch, for the treatment of postherpetic neuralgia. Pain Med. 2011;12:99–109.
100. Simpson DM, Brown S, Tobias J. Controlled trial of high-concentration capsaicin patch for treatment of painful HIV neuropathy. Neurology. 2008;70:2305–13.
101. Derry S, Sven-Rice A, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2013;2:CD007393.
102. Simpson DM, Brown S, Tobias JK, et al. NGX-4010, a capsaicin 8 % dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy: results of a 52-week open-label study. Clin J Pain. 2014;30:134–42.
103. Stoker M, Jacobs H, Lloyd A, et al. A Phase 3, double-blind, randomized, placebo-controlled, multicenter study evaluating the efficacy and safety of QUTENZA® (high concentration 8 % capsaicin patch) in subjects with painful diabetic peripheral neuropathy (pDPN). Abstract presented at the 4th Biannual International Multidisciplinary Pain Congress, Eindhoven, Netherlands; October 1–4, 2014. Abstract 51.
104. Astellas Pharma Inc. A study to evaluate the long-term safety of repeated QUTENZA administration for treatment of pain caused by nerve damage in diabetic patients (PACE). 2014. http://clinicaltrials.gov/ct2/show/NCT01478607?term=capsaicin+AND+diabetes&rank=4. Accessed 24 June 2014.
105. Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of combination therapy with 5 % lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin. 2009;25:1677–87.
106. National Institute for Health and Clinical Excellence. Neuropathic pain overview: pathway. http://pathways.nice.org.uk/pathways/neuropathic-pain. Accessed 24 June 2014.
107. Beaser RS, Okeke E, Neighbours J, et al. Coordinated primary and specialty care for type 2 diabetes mellitus, guidelines, and systems: an educational needs assessment. Endocr Pract. 2011;17:880–90.
108. Bowling FL, King L, Paterson JA, et al. Remote assessment of diabetic foot ulcers using a novel wound imaging system. Wound Repair Regen. 2011;19:25–30.
109. von dem Knesebeck O, Gerstenberger E, Link C, et al. Differences in the diagnosis and management of type 2 diabetes in 3 countries (US, UK, and Germany): results from a factorial experiment. Med Care. 2010;48:321–6.
110. Donker GA, Fleming DM, Schellevis FG, et al. Differences in treatment regimes, consultation frequency and referral patterns of diabetes mellitus in general practice in five European countries. Fam Pract. 2004;21:364–9.
111. Iyer S, Tanenberg RJ. Pharmacologic management of diabetic peripheral neuropathic pain. Expert Opin Pharmacother. 2013;14:1765–75.
112. Farber DC, Farber JS. Office-based screening, prevention, and management of diabetic foot disorders. Prim Care. 2007;34:873–85.
113. Geerts M, Landewe-Cleuren SA, Kars M, et al. Effective pharmacological treatment of painful diabetic neuropathy by nurse practitioners: results of an algorithm-based experience. Pain Med. 2012;13:1324–33.
114. Renders CM, Valk GD, Griffin SJ, et al. Interventions to improve the management of diabetes in primary care, outpatient, and community settings: a systematic review. Diabetes Care. 2001;24:1821–33.
115. Krishnan S, Nash F, Baker N, et al. Reduction in diabetic amputations over 11 years in a defined U.K. population: benefits of multidisciplinary team work and continuous prospective audit. Diabetes Care. 2008;31:99–101.
116. Malik RA, Tesfaye S, Ziegler D. Medical strategies to reduce amputation in patients with type 2 diabetes. Diabet Med. 2013;30:893–900.
117. Landon BE, Roberts DH. Reenvisioning specialty care and payment under global payment systems. JAMA. 2013;310:371–2.